Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Theranostics|January 7, 2020
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i><sup>18</sup>F-FDG-PETJohannes Schwenck, Barbara Schörg, Francesco Fiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Theranostics|January 7, 2020
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i><sup>18</sup>F-FDG-PETJohannes Schwenck, Barbara Schörg, Francesco Fiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Pageof 13